Clinical Trials Browser

Carcinoma, Hepatocellular, Liver Neoplasms

Nasopharyngeal Carcinoma

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Advanced Malignant Solid Tumors

Esophageal Squamous Cell Carcinoma

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Head and Neck Neoplasms

Small Cell Lung Carcinoma

Local Advanced Non-small Cell Lung Cancer

Carcinoma, Hepatocellular

Breast Neoplasms

Ovarian Neoplasms

Nasopharyngeal Carcinoma

Oropharyngeal Neoplasms

Small Cell Lung Cancer Limited Stage

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Pathologic Complete Response, Head and Neck Neoplasms

Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Uterine Cervical Neoplasms

Carcinoma, Transitional Cell

Advanced Lung Cancer

High-risk Renal Cell Carcinoma

Muscle-invasive Bladder Urothelial Carcinoma

Non-small Lung Cancer

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Triple Negative Breast Neoplasms

Turcot syndrome, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Clinical Trials

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

LIGHT

WOLF

TORCH-iTNT

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

(NeoScorch HN)

NEOTRIO-2

PLUTO

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

InTRist

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

IPROC

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

FACT-TN

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Toripalimab for High-risk Locally Advanced Cervical Cancer

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

TUORA

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Toripalimab Combined With SBRT for NSCLC

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

BCIRT-01

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

PICC

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer